IONIS PHARMACEUTICALS INC

NASDAQ: IONS (Ionis Pharmaceuticals, Inc.)

Kemas kini terakhir: 9 jam lalu

81.81

-0.03 (-0.04%)

Penutupan Terdahulu 81.84
Buka 81.51
Jumlah Dagangan 2,312,966
Purata Dagangan (3B) 2,489,809
Modal Pasaran 13,251,125,248
Harga / Pendapatan (P/E Ke hadapan) 90.91
Harga / Jualan (P/S) 13.47
Harga / Buku (P/B) 21.49
Julat 52 Minggu
23.95 (-70%) — 83.59 (2%)
Tarikh Pendapatan 29 Oct 2025
Margin Keuntungan -63.86%
Margin Operasi (TTM) -111.59%
EPS Cair (TTM) -2.99
Pertumbuhan Hasil Suku Tahunan (YOY) 10.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 413.80%
Nisbah Semasa (MRQ) 9.66
Aliran Tunai Operasi (OCF TTM) -501.78 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -368.16 M
Pulangan Atas Aset (ROA TTM) -10.59%
Pulangan Atas Ekuiti (ROE TTM) -118.62%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Ionis Pharmaceuticals, Inc. Menaik Menaik

AISkor Stockmoo

-0.3
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam -4.0
Volatiliti Harga -3.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal 4.0
Purata -0.30

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
IONS 13 B - - 21.49
NUVL 8 B - - 10.04
RYTM 7 B - - 48.92
PTCT 6 B - 9.05 -
SRRK 5 B - - 18.12
CRNX 4 B - - 4.03

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 0.83%
% Dimiliki oleh Institusi 108.17%

Pemilikan

Nama Tarikh Syer Dipegang
Tweedy, Browne Co Llc 30 Sep 2025 2,901,216
Julat 52 Minggu
23.95 (-70%) — 83.59 (2%)
Julat Harga Sasaran
65.00 (-20%) — 110.00 (34%)
Tinggi 110.00 (HC Wainwright & Co., 34.46%) Beli
Median 89.50 (9.40%)
Rendah 65.00 (Goldman Sachs, -20.55%) Pegang
Purata 86.64 (5.90%)
Jumlah 12 Beli, 2 Pegang
Harga Purata @ Panggilan 70.40
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 10 Nov 2025 110.00 (34.46%) Beli 69.54
30 Oct 2025 100.00 (22.23%) Beli 74.17
Piper Sandler 04 Nov 2025 77.00 (-5.88%) Beli 72.88
Barclays 30 Oct 2025 95.00 (16.12%) Beli 74.17
23 Sep 2025 80.00 (-2.21%) Beli 62.57
Morgan Stanley 30 Oct 2025 94.00 (14.90%) Beli 74.17
16 Oct 2025 90.00 (10.01%) Beli 73.07
Needham 30 Oct 2025 90.00 (10.01%) Beli 74.17
08 Oct 2025 78.00 (-4.66%) Beli 69.96
RBC Capital 30 Oct 2025 82.00 (0.23%) Beli 74.17
Raymond James 30 Oct 2025 89.00 (8.79%) Beli 74.17
TD Cowen 30 Oct 2025 99.00 (21.01%) Beli 74.17
JP Morgan 08 Oct 2025 80.00 (-2.21%) Beli 69.96
Oppenheimer 08 Oct 2025 90.00 (10.01%) Beli 69.96
Stifel 06 Oct 2025 67.00 (-18.10%) Pegang 69.02
Goldman Sachs 26 Sep 2025 65.00 (-20.55%) Pegang 64.09
B of A Securities 23 Sep 2025 83.00 (1.45%) Beli 62.57
Guggenheim 23 Sep 2025 92.00 (12.46%) Beli 62.57
Papar semua
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
DEVERS SHANNON L. - 80.93 -16,777 -1,357,763
KLEIN JOSEPH III - 80.93 -12,000 -971,160
WENDER JOSEPH H - 81.99 -28,000 -2,295,720
Jumlah Keseluruhan Kuantiti Bersih -56,777
Jumlah Keseluruhan Nilai Bersih ($) -4,624,643
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 81.28
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
WENDER JOSEPH H Pengarah 01 Dec 2025 Jual automatik (-) 28,000 81.99 2,295,720
DEVERS SHANNON L. Pegawai 25 Nov 2025 Jual automatik (-) 16,777 80.93 1,357,763
DEVERS SHANNON L. Pegawai 25 Nov 2025 Pelaksanaan pilihan 16,777 - -
KLEIN JOSEPH III Pengarah 25 Nov 2025 Jual automatik (-) 12,000 80.93 971,160
KLEIN JOSEPH III Pengarah 25 Nov 2025 Pelaksanaan pilihan 12,000 - -
Tarikh Jenis Butiran
02 Dec 2025 Pengumuman Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
01 Dec 2025 Pengumuman Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
14 Nov 2025 Pengumuman DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
13 Nov 2025 Pengumuman Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
12 Nov 2025 Pengumuman Ionis to present at upcoming investor conferences
11 Nov 2025 Pengumuman Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
08 Nov 2025 Pengumuman Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
06 Nov 2025 Pengumuman Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
29 Oct 2025 Pengumuman Ionis reports third quarter 2025 financial results and highlights progress on key programs
27 Oct 2025 Pengumuman Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
23 Oct 2025 Pengumuman Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
21 Oct 2025 Pengumuman Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
16 Oct 2025 Pengumuman Ionis to hold third quarter 2025 financial results webcast
07 Oct 2025 Pengumuman Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
22 Sep 2025 Pengumuman Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
19 Sep 2025 Pengumuman TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
12 Sep 2025 Pengumuman Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
09 Sep 2025 Pengumuman Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
08 Sep 2025 Pengumuman Ionis to host investors and analysts for Innovation Day 2025
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda